Adial Pharmaceuticals, Inc. Reimbursement from Limited Partnership Investment
Adial Pharmaceuticals, Inc. (ADIL) had Reimbursement from Limited Partnership Investment of $350.00 thousand as of 2023-09-20, per its 10-Q filed 2023-11-14.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:ReimbursementFromLimitedPartnershipInvestment · last filed 2023-11-14
- 2023-09-20: Reimbursement from Limited Partnership Investment $350.00K.
- 2023-06-30: Reimbursement from Limited Partnership Investment 6 month $350.00K.
| Period end | Reimbursement from Limited Partnership Investment | Reimbursement from Limited Partnership Investment 6 month |
|---|---|---|
| 2023-09-20 | $350.00K 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $350.00K 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |